Journal ArticleDOI
Treatment Options in Oligometastatic Disease in Prostate Cancer: Thinking Outside the Box
TLDR
Patients with up to five metastatic lesions should be considered for an oligometastatic treatment approach, and the addition of a second agent to ADT appears to be beneficial.Abstract:
Due to its relatively indolent disease course, the sensitivity of PSA testing, and the emergence of novel PET imaging, metastatic prostate cancer is particularly likely to present with a limited volume of disease. Patients with up to five metastatic lesions should be considered for an oligometastatic treatment approach. Systemic therapy remains the cornerstone of treatment for these patients. The optimal type and duration are unknown; however, the addition of a second agent to ADT appears to be beneficial. Multiple recent studies have found significant benefits to the integration of systemic therapy and local metastasis-directed therapies (MDT), including radiation and surgery, to the prostate and metastatic sites. MDT may also be used in select patients wishing to delay the initiation of systemic therapy. For patients with isolated regional nodal recurrences, whole pelvic radiotherapy or extensive lymphadenectomy is preferred, in combination with ADT.read more
Citations
More filters
Journal ArticleDOI
Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1
Sergey M. Deyev,Sergey M. Deyev,Sergey M. Deyev,Tianqi Xu,Yongsheng Liu,Alexey A. Schulga,Alexey A. Schulga,Elena Konovalova,Javad Garousi,Javad Garousi,Sara S. Rinne,Maria Larkina,Maria Larkina,Haozhong Ding,Torbjörn Gräslund,Anna Orlova,Anna Orlova,Anna Orlova,Vladimir Tolmachev,Vladimir Tolmachev,Anzhelika Vorobyeva,Anzhelika Vorobyeva +21 more
TL;DR: In this article, the influence of radiolabel position (N- or C-terminal) and composition on the targeting and imaging properties of ankyrin repeat protein (DARPin) Ec1 was investigated.
References
More filters
Journal ArticleDOI
Cancer statistics, 2020.
TL;DR: Slow momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers, and it is notable that long‐term rapid increases in liver cancer mortality have attenuated in women and stabilized in men.
Journal ArticleDOI
Natural history of progression after PSA elevation following radical prostatectomy.
Charles R. Pound,Alan W. Partin,Mario A. Eisenberger,Daniel W. Chan,Jay D. Pearson,Patrick C. Walsh +5 more
TL;DR: Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy, and these data may be useful in the design of clinical trials, the identification of men for enrollment into experimental protocols, and counseling men regarding the timing of administration of adjuvant therapies.
Journal ArticleDOI
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Robert C. Flanigan,Sydney E. Salmon,Brent A. Blumenstein,Scott I. Bearman,Vivek Roy,Patrick C. McGrath,John R. Caton,Nikhil C. Munshi,E. David Crawford +8 more
TL;DR: Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferons therapy alone.
Journal ArticleDOI
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James,Nicholas D. James,Matthew R. Sydes,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Melissa R. Spears,Alastair W. S. Ritchie,Chris Parker,J. Martin Russell,Gerhardt Attard,Johann S. de Bono,William Cross,Robert Jones,George N. Thalmann,Claire Amos,David Matheson,Robin Millman,Mymoona Alzouebi,Sharon Beesley,Alison Birtle,Susannah Brock,Richard Cathomas,Prabir Chakraborti,Simon Chowdhury,Audrey Cook,Tony Elliott,Joanna Gale,Stephanie Gibbs,John Graham,J. Hetherington,Robert Hughes,Robert W. Laing,Fiona McKinna,Duncan McLaren,Joe M. O'Sullivan,Omi Parikh,Clive Peedell,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Rajaguru Srinivasan,John Staffurth,Santhanam Sundar,Shaun Tolan,David Tsang,John Wagstaff,Mahesh K.B. Parmar +47 more
TL;DR: Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population of men, and heterogeneity in treatment effect across prespecified subsets was not found.
Journal ArticleDOI
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
TL;DR: Radical nephrectomy done before interferon-alfa-based immunotherapy might substantially delay time to progression and improve survival of patients with metastatic renal cell carcinoma who present with good performance status.